AMED Stock Recent News

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?

Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amedisys (AMED) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.03 per share a year ago.

BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025.

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.